Systemic Treatment of Body-Wide Duchenne Muscular Dystrophy Symptoms

Area of Science:

• Genetics and Molecular Biology
• Neuromuscular Disorders
• Cardiovascular Medicine

Background:

• Duchenne muscular dystrophy (DMD) is a fatal X-linked genetic disorder caused by the absence of dystrophin.
• Current therapeutic strategies primarily target skeletal muscle, the most visibly affected tissue in DMD.
• Emerging evidence indicates dystrophin's crucial role in various tissues, including cardiac muscle, smooth muscle, and the nervous system.

Purpose of the Study:

• To highlight the systemic nature of Duchenne muscular dystrophy (DMD) by emphasizing the ubiquitous expression of the dystrophin gene.
• To review current and emerging therapeutic strategies for DMD.
• To address unresolved questions concerning the function of different dystrophin isoforms and their therapeutic implications.

Main Methods:

• Review of existing literature on Duchenne muscular dystrophy (DMD) and dystrophin expression.
• Analysis of current therapeutic approaches and their limitations.
• Discussion of the role of various dystrophin isoforms in different tissues.

Main Results:

• The dystrophin gene is expressed ubiquitously across human tissues, not solely in skeletal muscle.
• Successful treatment of skeletal muscle in DMD may unmask or exacerbate latent phenotypes in cardiac and smooth muscle, potentially leading to adverse outcomes.
• Dystrophin deficiency impacts nervous system function, with shorter isoforms playing a significant role.

Conclusions:

• Duchenne muscular dystrophy (DMD) is a systemic disease requiring a comprehensive therapeutic approach.
• Current treatments focused on skeletal muscle may be insufficient and could potentially lead to detrimental effects in other tissues.
• Further research is needed to understand the function of distinct dystrophin isoforms and develop therapies that address the systemic manifestations of DMD.